Cationic Compounds for Ophthalmic Preservatives
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial and antimycotic agents used in ophthalmic preparations often have limited activity spectra and compatibility issues, particularly in the ophthalmic field, where they can cause side effects such as dry eye symptoms and cytotoxicity.
Innovation Solution
Development of cationic compounds with specific structural formulas that exhibit broad activity against bacteria and fungi, including Aspergillus brasiliensis, while maintaining high compatibility and non-irritating properties, suitable for use in ophthalmic formulations and other applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If benzalkonium chloride (BAC) is used as a preservative, then broad activity spectrum against bacteria and fungi is achieved, but cytotoxic effects and dry eye symptoms occur
Solution Approach 1:
The patent modifies the chemical structure of conventional quaternary ammonium compounds by replacing the traditional alkyl chain with a cycloaliphatic group (cyclohexyl, cyclopentyl, or cyclobutyl ring structure). This structural parameter change maintains the cationic charge and antimicrobial activity while reducing cytotoxicity and irritation to the eye, thereby resolving the contradiction between broad-spectrum efficacy and safety.
Solution Approach 2:
The invention creates a composite molecular structure combining the reactive quaternary ammonium center with stable cycloaliphatic rings. This composite approach integrates the antimicrobial functionality with reduced toxicity characteristics, achieving both broad activity spectrum and improved biocompatibility for ophthalmic applications.
2Object-affected harmful factors
If alternative preservatives such as Polyquad or sodium chlorite are used, then reduced toxicity is achieved, but activity spectrum against fungi is diminished
Solution Approach 1:
The patent adjusts the chemical parameters of the preservative by using cycloaliphatic-substituted quaternary ammonium compounds with specific ring structures and substituent patterns. This parameter optimization enables the compound to maintain effective antimycotic activity against fungi and yeasts while preserving the reduced toxicity profile of alternative preservatives, thus resolving the activity-spectrum limitation.
3Reliability
If boric acid or boric acid salts are combined with alternative preservatives, then antimycotic activity is improved, but compatibility and non-toxicity are compromised
Solution Approach 1:
The patent extracts and eliminates the need for boric acid combinations by incorporating direct antimycotic activity into the cycloaliphatic quaternary ammonium compound structure itself. The cycloaliphatic-substituted quaternary ammonium compounds inherently possess broad-spectrum antimicrobial and antimycotic properties, making the addition of boric acid unnecessary and thereby maintaining both efficacy and compatibility without compromise.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The invention relates to cationic compounds and their use as antimicrobial and antimycotic agents, in particular as disinfectants and preservatives in ophthalmic preparations.